STOCK TITAN

Pliant Therapeutics Inc - PLRX STOCK NEWS

Welcome to our dedicated news page for Pliant Therapeutics (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pliant Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pliant Therapeutics's position in the market.

Rhea-AI Summary
Pliant Therapeutics to participate in several investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences
-
Rhea-AI Summary
Pliant Therapeutics to present at ERS International Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
conferences
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (Nasdaq: PLRX) provided a corporate update and reported second quarter 2023 financial results. The company initiated the Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF and is expecting Phase 2a 12-week data of bexotegrast in patients with PSC in the third quarter of 2023. They also initiated the Phase 1 trial of PLN-101095 in patients with solid tumors resistant to checkpoint inhibitors. The company's financial results show a net loss of $41.2 million as of June 30, 2023, with cash, cash equivalents, and short-term investments of $555.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) announced the initiation of BEACON-IPF, a Phase 2b clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). The trial follows positive results from the Phase 2a INTEGRIS-IPF trial, demonstrating encouraging preliminary patient benefits for those on and off current background therapies. BEACON-IPF is a 52-week, multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2b trial evaluating bexotegrast at doses of 160 mg or 320 mg, planning to enroll approximately 270 patients with IPF at sites globally. The primary endpoint is the assessment of the change from baseline in absolute forced vital capacity (FVC) mL at Week 52.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
Pliant Therapeutics Inc

Nasdaq:PLRX

PLRX Rankings

PLRX Stock Data

852.38M
47.09M
6.63%
111.28%
12.39%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
South San Francisco

About PLRX

pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.